Product launch in dCELL® division
07/12/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221207:nRSG8347Ia&default-theme=true
RNS Number : 8347I Tissue Regenix Group PLC 07 December 2022
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Product launch in dCELL® division
Launch of VNEW® Fascia Lata allograft used to address stress urinary
incontinence
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces
the launch of VNEW® Fascia Lata allograft, an additional line extension to
the Company's dCELL® division.
The VNEW® Fascia Lata is a soft tissue allograft used to support weakened
tissue that can result in stress urinary incontinence ('SUI'), which affects
around one-third of adult women at some point in their lives(1). The number of
women undergoing surgery annually in the US for SUI is around 260,000(2).
The VNEW® Fascia Lata allograft is manufactured under an exclusive
arrangement for ARMS Medical ('ARMS'), a partner with which Tissue Regenix
entered into a multi-year exclusive distribution agreement (the 'Agreement')
in 2018. The VNEW® brand is owned by ARMS and consists of uniquely shaped
products that address pelvic health needs. The expansion of this Agreement
with ARMS adds VNEW® Fascia Lata to the exclusive distribution portfolio of
DermaPure® products to hospitals and surgeons throughout the US for use in
urology and gynaecology procedures.
Daniel Lee, CEO of Tissue Regenix, commented: "Following the successful launch
of VNEW® with ARMS Medical in September 2021
(https://www.londonstockexchange.com/news-article/TRX/launch-of-dermapure-r-meshed-and-vnewtm/15118072)
, we are very pleased to be continuing our partnership and launching the
VNEW® Fascia Lata allograft for surgical procedures to support tissue. The
diversification of our product portfolio will contribute to our market
penetration, as well as provide a significant improvement to quality of life
for those patients that receive these allografts."
Robert Greer, President & Founder of ARMS Medical, stated: "We continue to
be passionate about bringing innovative solutions to market for women
suffering from pelvic health issues. We are excited about the launch of VNEW®
Fascia Lata and credit our strategic partner, Tissue Regenix, and our strong
relationships with best-in-class surgeons for making this a reality. Annually,
there are over a quarter million women who can benefit and improve their
quality of life with ARMS Medical's VNEW® solutions."
(1)
https://www.urologyhealth.org/urology-a-z/s/stress-urinary-incontinence-(sui)
(https://www.urologyhealth.org/urology-a-z/s/stress-urinary-incontinence-(sui))
(2) https://www.intechopen.com/chapters/80860
(https://www.intechopen.com/chapters/80860)
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Tel: +44(0)20 7710 7600
Ben Maddison / Nick Harland / Kate Hanshaw
Walbrook PR Ltd Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of
regenerative medicine. The Company's patented decellularisation ('dCELL®')
technology removes DNA and other cellular material from animal and human soft
tissue, leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech
company that specialises in regenerative medicine and is dedicated to the
development of innovative osteoinductive and wound care scaffolds, which
enhance healing opportunities of defects created by trauma and disease.
CellRight®'s human osteobiologics may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END PRLXQLLBLLLEFBD